Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Oct 14;12:741623. doi: 10.3389/fphar.2021.741623

Parkia speciosa Hassk. Empty Pod Extract Alleviates Angiotensin II-Induced Cardiomyocyte Hypertrophy in H9c2 Cells by Modulating the Ang II/ROS/NO Axis and MAPK Pathway

Hawa Nordin Siti 1,2, Juriyati Jalil 3, Ahmad Yusof Asmadi 4, Yusof Kamisah 1,5,*
PMCID: PMC8551585  PMID: 34721028

Abstract

Cardiac hypertrophy is characteristic of heart failure in patients who have experienced cardiac remodeling. Many medicinal plants, including Parkia speciosa Hassk., have documented cardioprotective effects against such pathologies. This study investigated the activity of P. speciosa empty pod extract against cardiomyocyte hypertrophy in H9c2 cardiomyocytes exposed to angiotensin II (Ang II). In particular, its role in modulating the Ang II/reactive oxygen species/nitric oxide (Ang II/ROS/NO) axis and mitogen-activated protein kinase (MAPK) pathway was examined. Treatment with the extract (12.5, 25, and 50 μg/ml) prevented Ang II-induced increases in cell size, NADPH oxidase activity, B-type natriuretic peptide levels, and reactive oxygen species and reductions in superoxide dismutase activity. These were comparable to the effects of the valsartan positive control. However, the extract did not significantly ameliorate the effects of Ang II on inducible nitric oxide synthase activity and nitric oxide levels, while valsartan did confer such protection. Although the extract decreased the levels of phosphorylated extracellular signal-related kinase, p38, and c-Jun N-terminal kinase, valsartan only decreased phosphorylated c-Jun N-terminal kinase expression. Phytochemical screening identified the flavonoids rutin (1) and quercetin (2) in the extract. These findings suggest that P. speciosa empty pod extract protects against Ang II-induced cardiomyocyte hypertrophy, possibly by modulating the Ang II/ROS/NO axis and MAPK signaling pathway via a mechanism distinct from valsartan.

Keywords: Parkia speciosa, angiotensin II, NADPH oxidase, iNOS, ERK, p38, JNK

Introduction

Cardiac hypertrophy initially develops as an adaptive response to compensate for reduced cardiac function (Bernardo and McMullen, 2016). Unfortunately, the sustained effects of pathological stimuli promote pathophysiological changes that lead to cardiac remodeling and, ultimately, heart failure (Wang et al., 2016). Angiotensin II (Ang II), a potent stimulus of cardiac myocyte growth factors, has been found to be elevated in cardiac failure (Zucker et al., 2015). Ang II can be used to mimic pressure-overload-induced cardiac hypertrophy (Ying et al., 2014) and has been widely employed as a hypertrophic stimulus in various in vitro cardiac disease models (Ding et al., 2019).

Exposure to Ang II stimulates the development of cardiac hypertrophy by activating G-protein-coupled receptors, which, in turn, activate several cascades, including the Ang II/reactive oxygen species/nitric oxide (Ang II/ROS/NO) axis as well as signaling kinases and phosphatases (Takano et al., 2003). Substantial evidence has linked Ang II-stimulated pathways to the activation of NADPH oxidase (NOX), which is a significant source of ROS in cardiovascular cells (Nguyen Dinh Cat et al., 2013). ROS have been implicated in the activation of mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) pathways in Ang II-induced cardiac hypertrophy (Chen et al., 2020; Zhu et al., 2020). MAPK has three subfamilies—extracellular signal-related kinase (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 kinase (p38)—that have been reported to play a role in cardiac hypertrophy (Zhang et al., 2003; Muslin, 2008; Cheng et al., 2017). Ang II also causes cardiac inflammation by promoting inducible nitric oxide synthase (iNOS) activity (Huang et al., 2017). These overlapping pathways eventually lead to cardiac remodeling and hypertrophy.

A potential therapeutic target for halting the progression of cardiac failure involves the prevention of pathological cardiac hypertrophy, for which numerous studies have attempted to identify novel therapies. While no drugs directly or specifically targeting pathological cardiac hypertrophy have been identified (Tran et al., 2016), neurohormonal blockers have been found to reduce cardiac hypertrophy indirectly. Ethnopharmacology is a promising screening tool in drug discovery, and many medicinal plants, including Eriobotrya japonica (Thunb.) Lindl (Chiang et al., 2018) and Nelumbo nucifera Gaertn. (Cho et al., 2019), have been shown to display cardioprotective activity against Ang II-induced cardiomyocyte hypertrophy.

Parkia speciosa Hassk., a leguminous plant in the family Fabaceae, grows indigenously in Southeast Asia and has traditionally been used to manage hypertension (Azliza et al., 2012) and heart problems (Yullia, 2008). The plant’s empty pods have been reported to display various pharmacological activities, including anti-inflammatory (Mustafa et al., 2018; Gui et al., 2019a), antioxidant (Gui et al., 2019b), and α-glucosidase-inhibiting (Saleh et al., 2021) properties. Extracts from its pods contain a higher antioxidant capacity than its seeds (Kamisah et al., 2013), likely associated with the pod’s flavonoid and phenolic components, including gallic acid, quercetin, gossypetin, and catechin (Ko et al., 2014; Saleh et al., 2021). Experiments in hypertensive rats support the pods’ hypotensive and cardioprotective properties (Kamisah et al., 2017). However, their effects on cardiomyocyte hypertrophy have yet to be investigated. As plant extracts with high flavonoid content have been shown to protect against cardiomyocyte hypertrophy (Sun et al., 2018; Cho et al., 2019), this study aimed to investigate the effects of P. speciosa empty pod extract on the Ang II/ROS/NO axis and MAPK signaling pathway in Ang II-treated cardiomyocytes.

Materials and Methods

Materials

P. speciosa pods (Figure 1) were purchased from a local trader at Slim River, Perak, Malaysia (3°49′31.0ʺN 101°29′12.1ʺE) in January 2018. A voucher specimen (UKMB40383) was deposited at the Universiti Kebangsaan Malaysia Herbarium. H9c2 cardiomyocytes were obtained commercially (American Type Culture Collection, Rockville, MD, United States). All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, United States), and all antibodies for Western blotting were purchased from Cell Signaling Technology (Danvers, MA, United States) unless otherwise noted.

FIGURE 1.

FIGURE 1

Open in a new tab

(A) Parkia speciosa pods and (B) its slived deseeded pod.

Empty Pod Extraction

The pods were cleaned, deseeded, and dried at room temperature. The dried, empty pods were ground and extracted in 95% ethanol in a 100 g:1 L ratio at room temperature for 9 days (Ko et al., 2014), with the ethanol changed every 3 days to improve yield. The extract was then filtered through cotton wool, and the filtrate was concentrated with a rotary vacuum evaporator (Buchi Rotavapor R-200 System, Marshall Scientific, Hampton, NH, United States). After freeze-drying (Labconco, Kansas City, MO, United States) for 5 days, the powder was stored at 4°C.

Phytochemical Screening

Phytochemical screening was conducted using high-performance liquid chromatography (HPLC) following the method of Tuszyńska (2014) with some modifications. Briefly, P. speciosa extract powder was dissolved in 100% aqueous methanol (10 mg/ml) before filtering through a nylon membrane (0.45 µm) (#PP013045; Membrane Solutions, Auburn, WA, United States). Since hydrolyzed glycosides are not applicable for in vitro experiments, the extract was not subjected to acid hydrolysis. HPLC was performed on a C18 column (150 × 4.6 mm, 5 μm; Phenomenex, Torrance, CA) using a Waters Series 600 (Waters, Milford, MA) fitted with a photodiode array detector and an autosampler with an injection volume of 20 μl. The samples were isocratically eluted using 0.2% orthophosphoric acid in methanol/water (60/40) at 0.75 ml/min with detection at 370 nm. This procedure was repeated on three separate days (interday) with at least three replicates/day (intraday) to determine precision.

Peaks in the extract samples were compared to catechin (K4512), rutin (R5143), quercetin (Q4951), kaempferol (K0133), ellagic acid (E2250), gallic acid (27,645), and caffeic acid (C0625) standards. The area under the curve (AUC) was calculated for five concentrations (62.5–1,000 μg/ml) of each standard run in triplicate and was used to prepare calibration curves. Fitted equations for the calibration curves were used to calculate the concentration of the compounds in P. speciosa extract.

H9c2 Cell Culture

H9c2 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco BRL Life Technologies, Grand Island, NY, United States) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin G, and 100 μg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO2. The medium was changed every 2 d. The cells were grown to 60–70% confluency and serum-starved for 24 h prior to the experiment (Yan et al., 2013). Cells passaged 5–7 times and grown to a density of 1.6 × 104 cells/ml were used for the experiments.

Cytotoxicity Study

Cells were seeded in a 96-well plate and incubated with various concentrations of P. speciosa extract (3.125–400 μg/ml) for 24 h. Cell viability was assayed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS; Cat No: 197010, Abcam, Cambridge, United Kingdom) with detection at 490 nm. Dimethyl sulfoxide (DMSO) (<0.1%) was used as the vehicle for P. speciosa extract. A minimum of three biological replicates was performed in triplicate (n = 3).

Concentration-Response Study of P. speciosa Extract on H9c2 Cell Size

Cells were treated concurrently with Ang II (600 nM) (Siti et al., 2021) and various concentrations of P. speciosa extract (3.125–100 μg/ml) for 24 h in eight-well chamber slides. Cell size was measured using immunofluorescence staining. The best three extract concentrations for protecting against Ang II-induced cardiomyocyte hypertrophy were selected for further study. At least three biological replicates were performed in triplicate (n = 3).

Experimental Groups

H9c2 cells were randomly assigned to seven groups: 1) control (vehicle), 2) 50 μg/ml P. speciosa extract, 3) Ang II (600 nM; Siti et al., 2021), 4) Ang II and 12.5 μg/ml extract, 5) Ang II and 25 μg/ml extract, 6) Ang II and 50 μg/ml extract, and 7) Ang II and 20 μM valsartan (Al-Mazroua et al., 2013). Valsartan served as the positive control. Cells were treated concurrently with the extract and Ang II for 24 h.

Cell Size Quantification

Cell size was measured following the method of Jeong et al. (2015) with slight modifications described by Siti et al. (2021). Cells were stained with a primary antibody against α-actinin (1:200 dilution; ab9465, Abcam, Cambridge, MA, United States) followed by an Alexa Fluor 488-conjugated anti-mouse secondary antibody (1:200 dilution; A-11059, Invitrogen, Waltham, MA, United States) and visualized via fluorescence microscopy (Olympus Optical, Tokyo, Japan). A blinded assessor quantified the cardiomyocytes’ surface areas (>60 cells) using ImageJ software (U. S. National Institutes of Health, Bethesda, MD, United States) and compared them to control cells. A minimum of three biological replicates was performed in triplicate (n = 3).

Cellular B-Type Natriuretic Peptide and iNOS Levels

The cellular levels of B-type natriuretic peptide (BNP) and iNOS were estimated from cell lysates using commercial kits (Elabscience, Houston, TX, United States). Briefly, the biotinylated detection antibody and samples were incubated in micro-ELISA wells precoated with BNP or rat NOS2/iNOS antibodies, excess conjugates were removed, and an avidin-horseradish peroxidase (HRP) conjugate was added to develop a blue color. Upon addition of a stop solution, a yellow color change occurred, which was measured at 450 nm. BNP and iNOS levels were estimated against standard curves. A minimum of three biological replicates was performed in triplicate (n = 3).

Cellular Nitrite and Intracellular ROS Detection

Nitrite, a stable metabolite of NO, was measured following the method described by Siti et al. (2019). Cardiomyocytes were seeded in 96-well plates. Sample cell lysate (50 μl) was reacted with an equal volume of modified Griess reagent for 15 min at room temperature in the dark. The absorbance was measured at 540 nm (EnSpire® Multimode Plate Reader, PerkinElmer, Inc., MA, United States) and compared to a sodium nitrite standard curve to determine nitrite concentrations.

Global levels of ROS, including peroxynitrite and superoxide, were assessed in living cells using a commercial kit (ROS-ID® Total ROS/Superoxide Detection Kit, ENZ-51010, Enzo, NY, United States) according to the manufacturer’s protocol. Fluorescence signals were measured at 488 nm using a microplate reader (EnSpire® Multimode Plate Reader, PerkinElmer, Inc., MA, United States).

At least three biological replicates were performed in triplicate (n = 3) for all experiments.

NOX and Superoxide Dismutase Activities

NOX activity was measured according to the method described by Mustapha et al. (2010). Briefly, cell lysate (50 μg protein/sample), cytochrome c (250 μg/L), and NADPH (100 μM) were incubated at 37°C for 2 h with or without diphenyleneiodonium (DPI, 100 μM). The absorbance of the mixture was quantified at 550 nm. NOX activity was calculated using an extinction coefficient of 21 mMcm−1.

Superoxide dismutase (SOD) activity (U/mg of protein) was measured according to the procedure of Beyer and Fridovich (1987). Sample cell lysate (20 μl) and riboflavin (10 μl, 50 μM) were added into an assay mixture containing 27 ml of phosphate buffer (pH 7.8, 50 mM), EDTA (50 μM), 1.5 ml of L-methionine (20 mM), and 1 ml of nitroblue tetrazolium (1.5 mM). The mixture was illuminated for 7 min in an aluminum foil-coated box equipped with a 40 W fluorescent bulb, and absorbance was measured at 550 nm.

At least three biological replicates were performed in triplicate (n = 3) for all experiments.

Western Blot Analysis

Protein expression was measured by Western blot as previously described (Siti et al., 2021). Anti-phospho-ERK1/2 rabbit polyclonal (1:1,000) (#4377), anti-phospho-JNK1/2 rabbit monoclonal (1:1,000) (#4668), and anti-phospho-p38 mouse monoclonal (1:500) (sc-166182; Santa Cruz Biotechnology, Dallas, TX, United States) were the primary antibodies used in this study. β-Actin mouse monoclonal antibodies (1:500) (sc-47778; Santa Cruz Biotechnology, Dallas, TX, United States) served as the loading control. HRP-conjugated IgG anti-mouse (1:2000) (sc-516102; Santa Cruz Biotechnology, Dallas, TX, United States) was used as the secondary antibody. Blots were visualized on a gel doc system and analyzed with ImageJ software (U. S. National Institutes of Health, Bethesda, MD, United States). A minimum of three biological replicates was performed in triplicate (n = 3).

Statistical Analysis

All data are reported as mean ± standard error of the mean (SEM) from a minimum of three biological replicates performed in triplicate. The Shapiro-Wilk test was used to test for normality. Results were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test in SPSS version 24.0 software (IBM Corp., Armonk, NY, United States), with p < 0.05 considered significant.

Results

Phytochemical Screening of the Extract

There were 11 peaks detected in the sample extract chromatogram (Figure 2A). Two peaks were identified as rutin (1) and quercetin (2) (Figure 3) when compared against the peaks of the standards (Figure 2B). The remaining compounds could not be unequivocally identified owing to peak shape (blunted or multiple peaks). The retention time (tR) for rutin (1) and quercetin (2) in the extract resembled that of the standards (Table 1). Based on the rutin and quercetin calibration curves (Figure 4), the P. speciosa empty pod crude ethanolic extract contained 15.5 μg rutin/mg extract (1) and 0.11 μg quercetin/mg extract (2) (Table 2).

FIGURE 2.

FIGURE 2

Open in a new tab

Chromatographic analysis of (A) Parkia speciosa empty pod crude extract with detected rutin (1) and quercetin (2), and (B) the standard known compounds.

FIGURE 3.

FIGURE 3

Open in a new tab

The structure of (A) rutin (1) and (B) quercetin (2).

TABLE 1.

Retention time (tR) of quercetin and rutin in 10 mg Parkia speciosa crude extract compared to standard compounds.

Retention time, tR (min)
Sample Quercetin Rutin
Standard 6.168 ± 0.070 3.348 ± 0.025
P. speciosa extract 6.461 ± 0.171 3.551 ± 0.064
Open in a new tab

Values reported as mean ± SEM (n = 3). Each sample was measured at least three times on three different days.

FIGURE 4.

FIGURE 4

Open in a new tab

Calibration curves for (A) rutin and (B) quercetin.

TABLE 2.

Concentration of quercetin and rutin in 10 mg Parkia speciosa crude extract.

Area under the curve Concentration (µg/ml) Percentage (%)
Rutin 4,603,554 ± 250,,072 158.35 ± 7.02 1.58
Quercetin 1,168,863 ± 86,994 20.60 ± 1.53 0.21
Open in a new tab

Values reported as mean ± SEM (n = 3). Each sample was measured at least three times on three different days.

Extract Cytotoxicity

Treatment with 0.1% DMSO alone had no effect on cell viability as compared to the control (data not shown), indicating that its use as a vehicle for P. speciosa extract did not contribute to cytotoxicity. The median inhibitory concentration (IC50) of the extract was approximately 108.35 μg/ml (Figure 5). Subsequent experiments used sub-IC50 extract concentrations.

FIGURE 5.

FIGURE 5

Open in a new tab

Cell viability of H9c2 cells after 24 h exposure to Parkia speciosa empty pod extract at increasing concentrations. *p < 0.05 vs. control. Results are presented as the mean ± SEM (n = 3).

Optimizing Extract Concentration for Antihypertrophic Activity

Ang II-induced cardiomyocyte hypertrophy was significantly alleviated with 6.25, 12.5, 25, and 50 μg/ml extract (Figure 6). Cell size was significantly reduced at 100 μg/ml extract compared to both the control and Ang II treatments (p < 0.05). Based on these findings, 12.5, 25, and 50 μg/ml extract were used in the subsequent experiments.

FIGURE 6.

FIGURE 6

Open in a new tab

Effect of various concentrations of Parkia speciosa empty pod extract on cell size in H9c2 cells exposed to Ang II (600 nM) for 24 h. (A) Representative immunofluorescent image (magnification × 100) and (B) quantitative analysis of immunofluorescent cells. *p < 0.05 vs. control (no treatment) group. #p < 0.05 vs. Ang II group. Bars represent the mean ± SEM (n = 3).

Cell Size and BNP Levels

Ang II-treated cells showed a significant increase in cell size (1.52 ± 0.04 times) and cellular BNP levels (50.49 ± 1.16 ng/mg protein) compared to the control (27.29 ± 2.08 ng/mg protein) (Figure 7). Treatment with valsartan or the selected extract concentrations significantly reduced Ang II-induced changes in cell size and BNP levels (p < 0.05). There were no significant differences in these effects across the three extract concentrations or valsartan treatments. Treatment with 50 μg/ml extract alone did not significantly affect cell size or BNP levels.

FIGURE 7.

FIGURE 7

Open in a new tab

Effect of Parkia speciosa empty pod extract (μg/ml) or valsartan (20 μM, positive control) co-incubation on Ang II (600 nM)-induced H9c2 cell hypertrophy seen in (A) representative immunofluorescent-stained cells (magnification × 100), (B) cell surface area, and (C) B-type natriuretic peptide (BNP) after 24 h *p < 0.05 vs. control (no treatment) group. #p < 0.05 vs. Ang II group. Results are presented as the mean ± SEM (n = 3).

Intracellular ROS Levels and NOX and SOD Activities

While Ang II significantly increased the intracellular ROS levels and NOX activity and decreased the SOD activity in H9c2 cells compared to the control (Figures 8A–C), co-treatment with valsartan or the selected extract concentrations prevented these effects. There were no significant differences in intracellular ROS levels across the three extract concentrations. SOD activity was rescued similarly across all treatments. Treatment with 50 μg/ml extract alone did not significantly affect these parameters.

FIGURE 8.

FIGURE 8

Open in a new tab

(A) Cellular reactive oxygen species (ROS) level, (B) NADPH oxidase (NOX) activities, and (C) superoxide dismutase (SOD) activities in cells co-treated with Ang II (600 nM) and three concentrations of Parkia speciosa extract (μg/ml) or valsartan (20 μM, positive control) for 24 h *p < 0.05 vs. control (no treatment) group. #p < 0.05 vs. Ang II group. Bars represent means ± SEM (n = 3).

Cellular iNOS and Nitrite Levels

Ang II significantly increased H9c2 cellular iNOS levels (0.016 ± 0.002 pg/mg protein, p < 0.05) compared to the control (0.008 ± 0.001 pg/mg protein) (Figure 9A). While co-treatment with P. speciosa empty pod extract did not prevent this change, iNOS levels were rescued with valsartan (p < 0.05). Exposure to Ang II significantly reduced H9c2 cellular nitrite levels (18.96 ± 3.49 mM/mg protein, p < 0.05) compared to the control (31.79 ± 4.29 mM/mg protein) (Figure 9B). Neither valsartan nor the selected extract concentrations significantly prevented this change (p > 0.05). Treatment with 50 μg/ml extract alone did not significantly affect these parameters.

FIGURE 9.

FIGURE 9

Open in a new tab

Cellular (A) inducible nitric oxide synthase (iNOS) activity and (B) nitrite level in groups co-treated with Ang II (600 nM) and three concentrations of Parkia speciosa empty pod extract or valsartan (20 μM, positive control) for 24 h *p < 0.05 vs. control (no treatment) group. #p < 0.05 vs. Ang II cells. Bars represent means ± SEM (n = 3).

MAPK Protein Expression

After 24 h, Ang II-treated H9c2 cells expressed elevated levels of phosphorylated ERK1/2, p38, and JNK (p < 0.05) (Figure 10). Co-treatment with all three selected extract concentrations prevented these elevated levels to a similar extent, while valsartan only rescued p-JNK expression. Treatment with 50 μg/ml extract alone did not significantly affect MAPK protein expression.

FIGURE 10.

FIGURE 10

Open in a new tab

Effects of Parkia speciosa empty pod extract and valsartan (20 μM, positive control) on (A) representative immunoblots via Western blot analysis, quantitative analysis of phosphorylated (B) extracellular signal-related kinases (P-ERK1/2), (C) p38 kinase (P-p38), and (D) c-Jun N-terminal kinases (P-JNK) protein expressions in H9c2 cells that were exposed to Ang II (600 nM) for 24 h *p < 0.05 vs. control (no treatment) group. #p < 0.05 vs. Ang II cells. Bars represent means ± SEM (n = 3).

Discussion

Exposure to Ang II induced an ROS/NO axis imbalance, apparent in augmented intracellular superoxide/ROS (O2 −•/ROS) levels, increased NOX and iNOS activities, and decreased SOD activity. This imbalance led to cardiomyocyte hypertrophy, which manifested in increased cell size and elevated BNP levels, indicative of ventricular dysfunction. Ang II is reported to promote cardiac hypertrophy by stimulating growth factors (Ding et al., 2019). The findings of this study confirm previous reports regarding the involvement of oxidative stress in the development of Ang II-induced cardiomyocyte hypertrophy (Guan et al., 2017; Hong et al., 2019). Binding of Ang II to the Ang II type 1 receptor (AT1R) enhances the activation of NOX (Masi et al., 2019), which is a substantial producer of ROS, including O2 −• (Wen et al., 2019). The elevated levels of O2 −• detected in the H9c2 cells depleted the antioxidant SOD, which functions as a first line of defense against cardiomyocyte hypertrophy by converting the radical anion into water and hydrogen peroxide (Campos-Shimada et al., 2020).

The detrimental effects of Ang II on the ROS/NO axis were prevented by co-treating with P. speciosa empty pod extract. Notably, the cardioprotective effects of the extract were not concentration-dependent. These findings highlight the extract’s antioxidant properties, in agreement with previous work (Kamisah et al., 2017; Gui et al., 2019b). The empty pod extract was employed in this study as it is reported to contain a higher antioxidant capacity than the seed extract (Kamisah et al., 2013; Zaini and Mustaffa 2017). The cardioprotective effects of the extract are likely associated with its flavonoid content, with rutin (1) and quercetin (2) identified among its primary metabolites in this work. Studies have reported the presence of other flavonoids (Ko et al., 2014; Ghasemzadeh et al., 2018) not detected in this work, likely due to differences in chromatographic analysis. HPLC analysis in this study was unable to identify the remaining contents in the extract unambiguously, which may have included other flavonoids and phenolic acids. As these other metabolites could play a role in the cardioprotective effects of P. speciosa extract, additional studies should focus on their identification. The purpose of identifying the metabolites in this study was to aid in understanding how the extract could provide its cardioprotective effects. To determine the specific mechanisms by which the extract prevents cardiomyocyte hypertrophy, studies should investigate the activity of the individual extract components. For example, previous work using commercial quercetin and rutin demonstrated their antioxidant and antihypertrophic activities in Ang II-treated cardiomyocytes (Siti et al., 2021). Flavonoids, such as quercetin and rutin, can exert their antioxidant effects by binding SOD and increasing its activity (Cos et al., 1998; Zhuang et al., 2016). Metabolites in the extract may also directly prevent the prooxidant effects of Ang II itself.

Another source of cellular ROS is iNOS, which is upregulated in response to increased microenvironmental inflammation (Cinelli et al., 2020). Ang II was found to activate iNOS activity in this work, consistent with previous findings (Restini et al., 2017). Ang II promotes inflammation via activation of the NF-κB signaling pathway and the release of tumor necrosis factor-α (TNFα) and interleukin 6 (Huang et al., 2017). However, this study found that despite increasing iNOS activity, exposure to Ang II decreased NO levels. NO can react with O2 −• to generate peroxynitrite radicals (Radi, 2018), reducing its own level. Co-treatment with the extract did not prevent the harmful effects of Ang II on iNOS activity or NO levels. However, ethyl acetate fractions of the extract have been reported to reduce both parameters in cardiomyocytes and human umbilical vein endothelial cells exposed to TNFα (Mustafa et al., 2018; Gui JS. et al., 2019). The discrepancy between these findings could stem from differences in the models and the type of fraction used. Rutin (50 µM) and quercetin (331 µM) have been reported to reverse the effects of Ang II on iNOS activity and NO levels (Siti et al., 2021). The highest concentration of extract used in this work (50 μg/ml) contained much lower concentrations of the flavonoids [0.790 μg/ml rutin (1) and 0.105 μg/ml quercetin (2)], possibly rationalizing the poor protection.

Valsartan was used as the positive control in this work due to its ability to reduce cardiomyocyte hypertrophy and BNP levels (Xu et al., 2015; Wu et al., 2017), as well as its use in the clinical management of heart failure (Vaduganathan et al., 2020). The antioxidant activity of valsartan has manifested in suppressed ROS levels (Chen et al., 2014; Tian et al., 2018). Valsartan displayed similar protective effects against Ang II-induced cardiomyocyte hypertrophy and oxidative stress in this study. It acts as an AT1R blocker to prevent Ang II receptor activation and downstream pathological events. Valsartan demonstrated better anti-inflammatory properties than the extract in suppressing the negative effects of Ang II. Previous work reported similar beneficial effects of valsartan on iNOS expression (Mohammed et al., 2015).

Ang II treatment was found to increase the levels of phosphorylated ERK1/2, JNK1/2, and p38, consistent with previous studies (Sriramula and Francis, 2015; Yokota and Wang, 2016; Lu et al., 2020). Exposure to Ang II triggers signal transduction, which activates the MAPK cascade via phosphorylation of ERK1/2, JNK, and p38 prior to nuclear translocation. This leads to the activation of numerous transcription factors (Zhang et al., 2003), some of which regulate the expression of hypertrophic gene products, such as BNP (Nayer et al., 2014).

Treatment with P. speciosa extract reduced the expression of P-ERK, P-p38, and P-JNK, suggesting that its antihypertrophic activity may function via modulation of the MAPK signaling pathway. The extract may prevent Ang II from binding AT1R, suppressing downstream events leading to hypertrophy, although this requires further investigation. Quercetin (2) has been shown to block activation of the MAPK signaling pathway. As rutin (1) lacks this property (Siti et al., 2021), the inhibitory effects of the extract on the MAPK signaling pathway are most likely due to quercetin and/or other unidentified phytochemical contents. Nevertheless, both rutin and quercetin have been reported to ameliorate cardiac hypertrophy via multiple routes, including apoptosis, autophagy, and prohypertrophic pathways (Siti et al., 2020a; Siti et al., 2020b). Therefore, rutin may confer protection via mechanisms other than inhibition of MAPK signaling.

Apart from reducing P-JNK levels, valsartan had no effect on MAPK signaling. Similar effects have been reported for losartan, another AT1R blocker, in a study on myocardial hypertrophy in hypertensive rats (Izumi et al., 2000). Valsartan has been shown to mitigate the Ang II-induced activation of p38, ERK1/2, and JNK in HL-1 cardiomyocytes (Liu et al., 2015). These contradictory findings could derive from differences in the types of cells or models used. The findings in this work suggest that the cardioprotective effect of valsartan on cardiomyocyte hypertrophy occurs via modulation of the Ang II/ROS/NO axis rather than regulation of the MAPK pathway.

Few studies apart from this one have investigated the cardioprotective potential of P. speciosa extract. This study demonstrated the protective effects of P. speciosa empty pod extract against Ang II-induced cardiomyocyte hypertrophy in H9c2 cells (Figure 11), and may support the traditional use of the plant in ameliorating cardiac problems. The antihypertrophic properties of the extract were investigated by cotreating cardiomyocytes with extract and Ang II. While this study presents promising findings, the antihypertrophic effects of the extract should be investigated as a post-treatment in future investigations. Results from this work suggest that the extract could be used as a supplement to ameliorate cardiac remodeling, although further studies are required before clinical use. Future research should also explore other possible mechanisms of action, such as the extract’s effects on calcium regulatory proteins or other pathways, including the specificity protein-1/GATA binding protein-4 (Sp1/GATA4) or phosphatidylinositol 3-kinase/protein kinase B/glycogen synthase kinase-3β (PI3K/Akt/GSK-3β) signaling pathways in hypertrophied cardiomyocytes.

FIGURE 11.

FIGURE 11

Open in a new tab

Schematic summary of the possible site of cardioprotective effects of Parkia speciosa empty pod extract. AT1R, angiotensin II type 1 receptor; BNP, B-type natriuretic peptide; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; ERK1/2, extracellular signal-related kinase; iNOS, inducible nitric oxide synthase; JNK, c-Jun N-terminal kinase; MEF2, myocyte enhancer factor-2; NFAT, nuclear factor of activated T-cells; NF-κB, nuclear factor kappa B; NO, nitric oxide; PKG, protein kinase G; p38, p38 kinase; P-ERK1/2, phosphorylated extracellular signal-related kinase (ERK1/2), P-JNK, phosphorylated c-Jun N-terminal kinase; P-p38, phosphorylated p38 kinase; SOD, superoxide dismutase; SRF, serum response factor; ⊥, inhibition.

Conclusion

P. speciosa empty pod extract afforded protection against Ang II-induced cardiomyocyte hypertrophy by mitigating oxidative stress and modulating the MAPK signaling pathway. These effects may be attributed to its rich rutin (1) and quercetin (2) content. Notably, the protective effects of the extract appear to occur via mechanisms distinct from valsartan.

Acknowledgments

The authors would like to acknowledge technical assistance given by En Fadhlullah Zuhair Japar Sidik and Puan Juliana Abdul Hamid.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author Contributions

HS performed the experiments, as well as wrote the article. JJ supervised the extraction and phytochemical screening. AA and YK supervised the study. All authors designed the study, revised the article and approved its submission.

Funding

This study received a funding from the Faculty of Medicine, Universiti Kebangsaan Malaysia (FF-2019-021).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Glossary

Ang II

angiotensin II

ANOVA

one-way analysis of variance

AT1R

Ang II type 1 receptor

AUC

area under the curve

BNP

B-type natriuretic peptide

cGMP

cyclic guanosine monophosphate

DMEM

Dulbecco’s Modified Eagle Medium

DMSO

dimethyl sulfoxide

DPI

diphenyleneiodonium

EDTA

ethylenediaminetetraacetic acid

ELISA

enzyme-linked immunosorbent assay

eNOS

endothelial nitric oxide synthase

ERK1/2

extracellular signal-related kinase

FBS

fetal bovine serum

HPLC

high-performance liquid chromatography

HRP

horseradish peroxidase

IC50

median inhibitory concentration

iNOS

inducible nitric oxide synthase

JNK

c-Jun N-terminal kinase

MAPK

mitogen-activated protein kinase

MEF2

myocyte enhancer factor-2

MTS

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

NADPH

nicotinamide adenine dinucleotide phosphate

NF-κB

nuclear factor kappa-B

NO

nitric oxide

NOX

NADPH oxidase

NFAT

nuclear factor of activated T-cells

NOS2

nitric oxide synthase 2

O2 −•

superoxide anion

P-ERK1/2

phosphorylated ERK1/2

p38

p38 kinase

PI3K/Akt/GSK-3β

phosphatidylinositol 3-kinase/protein kinase B/glycogen synthase kinase-3β

P-p38

phosphorylated p38

P-JNK

phosphorylated JNK

PKG

protein kinase G

ROS

reactive oxygen species

SEM

standard error of the mean

SOD

superoxide dismutase

Sp1/GATA4

specificity protein-1/GATA binding protein-4

SPSS

Statistical Product and Service Solutions

SRF

serum response factor

TNFα

tumor necrosis factor-α

tR

retention time

References

  1. Al-Mazroua H. A., Al-Rasheed N. M., Korashy H. M. (2013). Downregulation of the Cardiotrophin-1 Gene Expression by Valsartan and Spironolactone in Hypertrophied Heart Rats In Vivo and Rat Cardiomyocyte H9c2 Cell Line In Vitro: A Novel Mechanism of Cardioprotection. J. Cardiovasc. Pharmacol. 61 (4), 337–344. 10.1097/FJC.0b013e318283a565 [DOI] [PubMed] [Google Scholar]
  2. Azliza M. A., Ong H. C., Vikineswary S., Noorlidah A., Haron N. W. (2012). Ethno-medicinal Resources Used by the Temuan in Ulu Kuang Village. Stud. Ethno-Medicine 6 (1), 17–22. 10.1080/09735070.2012.11886415 [DOI] [Google Scholar]
  3. Bernardo B. C., McMullen J. R. (2016). Molecular Aspects of Exercise-Induced Cardiac Remodeling. Cardiol. Clin. 34 (4), 515–530. 10.1016/j.ccl.2016.06.002 [DOI] [PubMed] [Google Scholar]
  4. Beyer W. F., Fridovich I. (1987). Assaying for Superoxide Dismutase Activity: Some Large Consequences of Minor Changes in Conditions. Anal. Biochem. 161 (2), 559–566. 10.1016/0003-2697(87)90489-1 [DOI] [PubMed] [Google Scholar]
  5. Campos-Shimada L. B., Hideo Gilglioni E., Fernandes Garcia R., Rizato Martins-Maciel E., Luiza Ishii-Iwamoto E., Luzia Salgueiro-Pagadigorria C. (2020). Superoxide Dismutase: a Review and a Modified Protocol for Activities Measurements in Rat Livers. Arch. Physiol. Biochem. 126 (4), 292–299. 10.1080/13813455.2018.1520891 [DOI] [PubMed] [Google Scholar]
  6. Chen G., Pan S. Q., Shen C., Pan S. F., Zhang X. M., He Q. Y. (2014). Puerarin Inhibits Angiotensin II-Induced Cardiac Hypertrophy via the Redox-Sensitive ERK1/2, P38 and NF-Κb Pathways. Acta Pharmacol. Sin. 35 (4), 463–475. 10.1038/aps.2013.185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen Y., Ge Z., Huang S., Zhou L., Zhai C., Chen Y., et al. (2020). Delphinidin Attenuates Pathological Cardiac Hypertrophy via the AMPK/NOX/MAPK Signaling Pathway. Aging (Albany NY) 12 (6), 5362–5383. 10.18632/aging.102956 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cheng C. I., Lee Y. H., Chen P. H., Lin Y. C., Chou M. H., Kao Y. H. (2017). Cobalt Chloride Induces RhoA/ROCK Activation and Remodeling Effect in H9c2 Cardiomyoblasts: Involvement of PI3K/Akt and MAPK Pathways. Cell Signal 36, 25–33. 10.1016/j.cellsig.2017.04.013 [DOI] [PubMed] [Google Scholar]
  9. Chiang J. T., Badrealam K. F., Shibu M. A., Kuo C. H., Huang C. Y., Chen B. C., et al. (2018). Eriobotrya Japonica Ameliorates Cardiac Hypertrophy in H9c2 Cardiomyoblast and in Spontaneously Hypertensive Rats. Environ. Toxicol. 33 (11), 1113–1122. 10.1002/tox.22589 [DOI] [PubMed] [Google Scholar]
  10. Cho S., Cho H. W., Woo K. W., Jeong J., Lim J., Park S., et al. (2019). Nelumbo nucifera Receptaculum Extract Suppresses Angiotensin II-Induced Cardiomyocyte Hypertrophy. Molecules 24 (9), 1647. 10.3390/molecules24091647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cinelli M. A., Do H. T., Miley G. P., Silverman R. B. (2020). Inducible Nitric Oxide Synthase: Regulation, Structure, and Inhibition. Med. Res. Rev. 40 (1), 158–189. 10.1002/med.21599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cos P., Ying L., Calomme M., Hu J. P., Cimanga K., Van Poel B., et al. (1998). Structure-activity Relationship and Classification of Flavonoids as Inhibitors of Xanthine Oxidase and Superoxide Scavengers. J. Nat. Prod. 61 (1), 71–76. 10.1021/np970237h [DOI] [PubMed] [Google Scholar]
  13. Ding J., Tang Q., Luo B., Zhang L., Lin L., Han L., et al. (2019). Klotho Inhibits Angiotensin II-Induced Cardiac Hypertrophy, Fibrosis, and Dysfunction in Mice through Suppression of Transforming Growth Factor-Β1 Signaling Pathway. Eur. J. Pharmacol. 859, 172549. 10.1016/j.ejphar.2019.172549 [DOI] [PubMed] [Google Scholar]
  14. Ghasemzadeh A., Jaafar H. Z. E., Bukhori M. F. M., Rahmat M. H., Rahmat A. (2018). Assessment and Comparison of Phytochemical Constituents and Biological Activities of Bitter Bean (Parkia Speciosa Hassk.) Collected from Different Locations in Malaysia. Chem. Cent. J. 12 (1), 12. 10.1186/s13065-018-0377-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Guan X. H., Hong X., Zhao N., Liu X. H., Xiao Y. F., Chen T. T., et al. (2017). CD38 Promotes Angiotensin II-Induced Cardiac Hypertrophy. J. Cel. Mol. Med. 21 (8), 1492–1502. 10.1111/jcmm.13076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gui J. S., Jalil J., Jubri Z., Kamisah Y. (2019a). Parkia Speciosa Empty Pod Extract Exerts Anti-inflammatory Properties by Modulating NFκB and MAPK Pathways in Cardiomyocytes Exposed to Tumor Necrosis Factor-α. Cytotechnology 71, 79–89. 10.1007/s10616-018-0267-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gui J. S., Mustafa N., Jalil J., Jubri Z., Kamisah Y. (2019b). Modulation of NOX4 and MAPK Signalling Pathways by Parkia Speciosa Empty Pods in H9c2 Cardiomyocytes Exposed to H2O2 . Indian J. Pharm. Sci. 81, 1029–1035. 10.36468/pharmaceutical-sciences.600 [DOI] [Google Scholar]
  18. Hong E. Y., Kim T. Y., Hong G. U., Kang H., Lee J. Y., Park J. Y., et al. (2019). Inhibitory Effects of Roseoside and Icariside E4 Isolated from a Natural Product Mixture (No-Ap) on the Expression of Angiotensin Ii Receptor 1 and Oxidative Stress in Angiotensin II-Stimulated H9C2 Cells. Molecules 24 (3), 414. 10.3390/molecules24030414 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Huang X., Wang Y., Zhang Z., Wang Y., Chen X., Wang Y., et al. (2017). Ophiopogonin D and EETs Ameliorate Ang II-Induced Inflammatory Responses via Activating PPARα in HUVECs. Biochem. Biophys. Res. Commun. 490 (2), 123–133. 10.1016/j.bbrc.2017.06.007 [DOI] [PubMed] [Google Scholar]
  20. Izumi Y., Kim S., Zhan Y., Namba M., Yasumoto H., Iwao H. (2000). Important Role of Angiotensin II-Mediated C-Jun NH(2)-terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats. Hypertension 36 (4), 511–516. 10.1161/01.hyp.36.4.511 [DOI] [PubMed] [Google Scholar]
  21. Jeong M. H., Kim S. J., Kang H., Park K. W., Park W. J., Yang S. Y., et al. (2015). Cucurbitacin I Attenuates Cardiomyocyte Hypertrophy via Inhibition of Connective Tissue Growth Factor (CCN2) and TGF- β/Smads Signalings. PLoS One 10, e0136236. 10.1371/journal.pone.0136236 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kamisah Y., Othman F., Qodriyah H. M., Jaarin K. (2013). Parkia Speciosa Hassk.: A Potential Phytomedicine. Evid. Based Complement. Alternat Med. 2013, 709028. 10.1155/2013/709028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kamisah Y., Zuhair J. S. F., Juliana A. H., Jaarin K. (2017). Parkia Speciosa Empty Pod Prevents Hypertension and Cardiac Damage in Rats Given N(G)-nitro-L-arginine Methyl Ester. Biomed. Pharmacother. 96, 291–298. 10.1016/j.biopha.2017.09.095 [DOI] [PubMed] [Google Scholar]
  24. Ko H.-J., Ang L.-H., Ng L.-T. (2014). Antioxidant Activities and Polyphenolic Constituents of Bitter BeanParkia Speciosa. Int. J. Food Properties 17 (9), 1977–1986. 10.1080/10942912.2013.775152 [DOI] [Google Scholar]
  25. Liu L., Geng J., Zhao H., Yun F., Wang X., Yan S., et al. (2015). Valsartan Reduced Atrial Fibrillation Susceptibility by Inhibiting Atrial Parasympathetic Remodeling through MAPKs/Neurturin Pathway. Cell. Physiol. Biochem. 36 (5), 2039–2050. 10.1159/000430171 [DOI] [PubMed] [Google Scholar]
  26. Lu Y., Sun X., Peng L., Jiang W., Li W., Yuan H., et al. (2020). Angiotensin II-Induced Vascular Remodeling and Hypertension Involves Cathepsin L/V- MEK/ERK Mediated Mechanism. Int. J. Cardiol. 298, 98–106. 10.1016/j.ijcard.2019.09.070 [DOI] [PubMed] [Google Scholar]
  27. Masi S., Uliana M., Virdis A. (2019). Angiotensin II and Vascular Damage in Hypertension: Role of Oxidative Stress and Sympathetic Activation. Vascul Pharmacol. 115, 13–17. 10.1016/j.vph.2019.01.004 [DOI] [PubMed] [Google Scholar]
  28. Mohammed H. E., Askar M. E., Ali S. I., Fathy O. M. (2015). Effect of Rennin Inhibitors and Sngiotensin II Receptor Antagonists on Left Ventricular Hypertrophy in Renovascular Hypertensive Rats. Int. J. Pharm. Pharm. Sci. 7 (9), 292–298. [Google Scholar]
  29. Muslin A. J. (2008). MAPK Signalling in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Targets. Clin. Sci. (Lond) 115 (7), 203–218. 10.1042/CS20070430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mustafa N. H., Ugusman A., Jalil J., Kamisah Y. (2018). Anti-inflammatory Property of Parkia Speciosa Empty Pod Extract in Human Umbilical Vein Endothelial Cells. J. App Pharm. Sci. 8, 152–158. 10.7324/JAPS.2018.8123 [DOI] [Google Scholar]
  31. Mustapha N. M., Tarr J. M., Kohner E. M., Chibber R. (2010). NADPH Oxidase versus Mitochondria-Derived ROS in Glucose-Induced Apoptosis of Pericytes in Early Diabetic Retinopathy. J. Ophthalmol. 2010, 746978. 10.1155/2010/746978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Nayer J., Aggarwal P., Galwankar S. (2014). Utility of point-of-care Testing of Natriuretic Peptides (Brain Natriuretic Peptide and N-Terminal Pro-brain Natriuretic Peptide) in the Emergency Department. Int. J. Crit. Illn. Inj. Sci. 4 (3), 209–215. 10.4103/2229-5151.141406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nguyen Dinh Cat A., Montezano A. C., Burger D., Touyz R. M. (2013). Angiotensin II, NADPH Oxidase, and Redox Signaling in the Vasculature. Antioxid. Redox Signal. 19 (10), 1110–1120. 10.1089/ars.2012.4641 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Radi R. (2018). Oxygen Radicals, Nitric Oxide, and Peroxynitrite: Redox Pathways in Molecular Medicine. Proc. Natl. Acad. Sci. U S A. 115, 5839–5848. 10.1073/pnas.1804932115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Restini C. B. A., Garcia A. F. E., Natalin H. M., Natalin G. M., Rizzi E. (2017). “Signaling Pathways of Cardiac Remodeling Related to Angiotensin II,” in Renin-Angiotensin System: Past, Present and Future. Editor Tolekova A. N.. Rijeka, Croatia: IntechOpen, 51–68. 10.5772/66076 [DOI] [Google Scholar]
  36. Saleh M. S. M., Jalil J., Mustafa N. H., Ramli F. F., Asmadi A. Y., Kamisah Y. (2021). UPLC-MS-Based Metabolomics Profiling for α-Glucosidase Inhibiting Property of Parkia Speciosa Pods. Life 11 (2), 78. 10.3390/life11020078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Siti H. N., Jalil J., Asmadi A. Y., Kamisah Y. (2021). Rutin Modulates MAPK Pathway Differently from Quercetin in Angiotensin II-Induced H9c2 Cardiomyocyte Hypertrophy. Int. J. Mol. Sci. 22 (10), 5063. 10.3390/ijms22105063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Siti H. N., Kamisah Y., Mohamed S., Jaarin K. (2019). Effects of Citrus Leaf Extract on Aortic Vascular Reactivity in Hypertensive Rats Fed Repeatedly Heated Vegetable Oil. Appl. Physiol. Nutr. Metab. 44 (4), 373–380. 10.1139/apnm-2018-0175 [DOI] [PubMed] [Google Scholar]
  39. Siti H. N., Jalil J., Asmadi A. Y., Kamisah Y. (2020b). Effects of Quercetin on Cardiac Function in Pressure Overload and Postischemic Cardiac Injury in Rodents: a Systematic Review and Meta-Analysis. Cardiovasc. Drugs Ther 10.1007/s10557-020-07100-y [DOI] [PubMed] [Google Scholar]
  40. Siti H. N., Jalil J., Asmadi A. Y., Kamisah Y. (2020a). Roles of Rutin in Cardiac Remodeling. J. Funct. Foods 64, 103606. 10.1016/j.jff.2019.103606 [DOI] [Google Scholar]
  41. Sriramula S., Francis J. (2015). Tumor Necrosis Factor - Alpha Is Essential for Angiotensin II-Induced Ventricular Remodeling: Role for Oxidative Stress. PLoS One 10 (9), e0138372. 10.1371/journal.pone.0138372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sun S., Li T., Jin L., Piao Z. H., Liu B., Ryu Y., et al. (2018). Dendropanax Morbifera Prevents Cardiomyocyte Hypertrophy by Inhibiting the Sp1/GATA4 Pathway. Am. J. Chin. Med. 46 (5), 1021–1044. 10.1142/S0192415X18500532 [DOI] [PubMed] [Google Scholar]
  43. Takano H., Zou Y., Hasegawa H., Akazawa H., Nagai T., Komuro I. (2003). Oxidative Stress-Induced Signal Transduction Pathways in Cardiac Myocytes: Involvement of ROS in Heart Diseases. Antioxid. Redox Signal. 5 (6), 789–794. 10.1089/152308603770380098 [DOI] [PubMed] [Google Scholar]
  44. Tian H., Yu D., Hu Y., Zhang P., Yang Y., Hu Q., et al. (2018). Angiotensin II Upregulates Cyclophilin A by Enhancing ROS Production in Rat Cardiomyocytes. Mol. Med. Rep. 18 (5), 4349–4355. 10.3892/mmr.2018.9448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Tran H. A., Lin F., Greenberg B. H. (2016). Potential New Drug Treatments for Congestive Heart Failure. Expert Opin. Investig. Drugs 25 (7), 811–826. 10.1080/13543784.2016.1181749 [DOI] [PubMed] [Google Scholar]
  46. Tuszyńska M. (2014). Validation of the Analytical Method for the Determination of Flavonoids in Broccoli. J. Hortic. Res. 22 (1), 131–140. 10.2478/johr-2014-0016 [DOI] [Google Scholar]
  47. Vaduganathan M., Claggett B. L., Desai A. S., Anker S. D., Perrone S. V., Janssens S., et al. (2020). Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/valsartan Compared with Valsartan in HFpEF. J. Am. Coll. Cardiol. 75 (3), 245–254. 10.1016/j.jacc.2019.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wang K., Long B., Liu F., Wang J. X., Liu C. Y., Zhao B., et al. (2016). A Circular RNA Protects the Heart from Pathological Hypertrophy and Heart Failure by Targeting miR-223. Eur. Heart J. 37 (33), 2602–2611. 10.1093/eurheartj/ehv713 [DOI] [PubMed] [Google Scholar]
  49. Wen Y., Liu R., Lin N., Luo H., Tang J., Huang Q., et al. (2019). NADPH Oxidase Hyperactivity Contributes to Cardiac Dysfunction and Apoptosis in Rats with Severe Experimental Pancreatitis through ROS-Mediated MAPK Signaling Pathway. Oxid. Med. Cel. Longev. 2019, 4578175. 10.1155/2019/4578175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Xu W. P., Yao T. Q., Jiang Y. B., Zhang M. Z., Wang Y. P., Yu Y., et al. (2015). Effect of the Angiotensin II Receptor Blocker Valsartan on Cardiac Hypertrophy and Myocardial Histone Deacetylase Expression in Rats with Aortic Constriction. Exp. Ther. Med. 9 (6), 2225–2228. 10.3892/etm.2015.2374 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Yan L., Zhang J. D., Wang B., Lv Y. J., Jiang H., Liu G. L., et al. (2013). Quercetin Inhibits Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats and Inhibits Angiotensin II-Induced H9C2 Cells Hypertrophy by Enhancing PPAR-γ Expression and Suppressing AP-1 Activity. PLoS One 8 (9), e72548. 10.1371/journal.pone.0072548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Ying H., Xu M. C., Tan J. H., Shen J. H., Wang H., Zhang D. F. (2014). Pressure Overload-Induced Cardiac Hypertrophy Response Requires Janus Kinase 2-histone Deacetylase 2 Signaling. Int. J. Mol. Sci. 15 (11), 20240–20253. 10.3390/ijms151120240 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Yokota T., Wang Y. (2016). p38 MAP Kinases in the Heart. Gene 575 (2 Pt 2), 369–376. 10.1016/j.gene.2015.09.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Yullia T. (2008). “Prakata,” in Variasi Masakan Petai & Jengkol, Tim Dapur DeMedia (Jakarta Selatan, DeMedia Pustaka). Jakarta Selatan and DeMedia, 2. [Google Scholar]
  55. Zaini N., Mustaffa F. (2017). Review: Parkia Speciosa as Valuable, Miracle of Nature. Ajmah 2 (3), 1–9. 10.9734/AJMAH/2017/30997 [DOI] [Google Scholar]
  56. Zhang W., Elimban V., Nijjar M. S., Gupta S. K., Dhalla N. S. (2003). Role of Mitogen-Activated Protein Kinase in Cardiac Hypertrophy and Heart Failure. Exp. Clin. Cardiol. 8 (4), 173–183. [PMC free article] [PubMed] [Google Scholar]
  57. Zhu W., Wu R. D., Lv Y. G., Liu Y. M., Huang H., Xu J. Q. (2020). BRD4 Blockage Alleviates Pathological Cardiac Hypertrophy through the Suppression of Fibrosis and Inflammation via Reducing ROS Generation. Biomed. Pharmacother. 121, 109368. 10.1016/j.biopha.2019.109368 [DOI] [PubMed] [Google Scholar]
  58. Zhuang X., Zhao B., Liu S., Song F., Cui F., Liu Z., et al. (2016). Noncovalent Interactions between Superoxide Dismutase and Flavonoids Studied by Native Mass Spectrometry Combined with Molecular Simulations. Anal. Chem. 88 (23), 11720–11726. 10.1021/acs.analchem.6b03359 [DOI] [PubMed] [Google Scholar]
  59. Zucker I. H., Schultz H. D., Patel K. P., Wang H. (2015). Modulation of Angiotensin II Signaling Following Exercise Training in Heart Failure. Am. J. Physiol. Heart Circ. Physiol. 308 (8), H781–H791. 10.1152/ajpheart.00026.2015 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES